APOGENIX Gmbh

The Apogenix team has developed a promising portfolio of innovative protein therapeutics for the treatment of cancer and other malignant diseases since the foundation of the company in 2005. These proteins target critical pathways involved in the growth, migration, and apoptosis of diseased cells and could thus transform the treatment of oncological and hematological diseases. The company’s lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma – only six years after the first publication of preclinical data that laid the foundation for the use of APG101 to treat this devastating disease. APG101 is currently being evaluated in a phase I trial for the treatment of myelodysplastic syndromes (MDS). APG101’s unique mode of action supports its significant potential for the treatment of other solid tumors beyond glioblastoma. Apogenix’ highly qualified scientific team has also developed a proprietary technology platform for the development of novel fusion proteins. These fusion proteins offer clear therapeutic advantages over other biologics such as antibodies and have the potential for broad application in oncology. Apogenix has successfully out-licensed its first program based on this technology platform – APG880 and derivatives – to a large pharmaceutical company.